BTAI BioXcel Therapeutics Inc

Price (delayed)

$31.05

Market cap

$764.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.06

Enterprise value

$572.14M

Sector: Healthcare
Industry: Biotechnology

Highlights

The equity has surged by 157% year-on-year but it has declined by 10% since the previous quarter
BTAI's quick ratio has surged by 141% year-on-year but it is down by 13% since the previous quarter
BioXcel Therapeutics's net income has shrunk by 130% YoY and by 14% QoQ
BTAI's EPS has dropped by 73% year-on-year and by 7% since the previous quarter

Key stats

What are the main financial stats of BTAI
Market
Shares outstanding
24.63M
Market cap
$764.82M
Enterprise value
$572.14M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.09
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$93.62M
EBITDA
-$93.41M
Free cash flow
-$74.45M
Per share
EPS
-$4.06
Free cash flow per share
-$3.04
Book value per share
$7.6
Revenue per share
$0
TBVPS
$8.17
Balance sheet
Total assets
$200.39M
Total liabilities
$13.65M
Debt
$1.33M
Equity
$186.74M
Working capital
$184.46M
Liquidity
Debt to equity
0.01
Current ratio
15.97
Quick ratio
15.74
Net debt/EBITDA
2.06
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-51.3%
Return on equity
-56.1%
Return on invested capital
N/A
Return on capital employed
-49.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BTAI stock price

How has the BioXcel Therapeutics stock price performed over time
Intraday
-1.33%
1 week
2.14%
1 month
-11.16%
1 year
-34.16%
YTD
-32.79%
QTD
-28.06%

Financial performance

How have BioXcel Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$93.68M
Net income
-$93.63M
Gross margin
N/A
Net margin
N/A
BioXcel Therapeutics's net income has shrunk by 130% YoY and by 14% QoQ
The company's operating income has shrunk by 127% YoY and by 14% QoQ

Growth

What is BioXcel Therapeutics's growth rate over time

Valuation

What is BioXcel Therapeutics stock price valuation
P/E
N/A
P/B
4.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
BTAI's EPS has dropped by 73% year-on-year and by 7% since the previous quarter
The equity has surged by 157% year-on-year but it has declined by 10% since the previous quarter
BTAI's price to book (P/B) is 54% lower than its last 4 quarters average of 8.9

Efficiency

How efficient is BioXcel Therapeutics business performance
The company's return on equity rose by 45% YoY and by 6% QoQ
BioXcel Therapeutics's return on assets has increased by 37% YoY and by 3.9% QoQ

Dividends

What is BTAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BTAI.

Financial health

How did BioXcel Therapeutics financials performed over time
BTAI's quick ratio has surged by 141% year-on-year but it is down by 13% since the previous quarter
BTAI's current ratio has soared by 134% YoY but it is down by 13% from the previous quarter
BTAI's debt is 99% smaller than its equity
The equity has surged by 157% year-on-year but it has declined by 10% since the previous quarter
BTAI's debt is up by 38% year-on-year but it is down by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.